SNU-5 In Vitro Reporter Gene (β-galactosidase) Assay

This assay is to provide SNU-5-based In Vitro Reporter Gene (β-galactosidase) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SNU-5

Human

SNU-5 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The patient had previously received chemotherapy including 5-fluorouracil, doxorubicin and mitomycin-C.
Derived from metastatic site, ascites

Gastric Carcinoma

Oncology

In Vitro Reporter Gene (β-galactosidase) Assay

SNU-5-cell based In Vitro Reporter Gene (β-galactosidase) Assay

Reporter gene assays have become a valuable technique for studying gene expression by both cis- and trans-acting regulatory factors. The action of a reporter gene is evaluated in a reporter gene assay and a reporter gene construct normally comprises of a target regulatory DNA sequence (usually a major in a cancer pathway) to be analyzed, sequence for the reported gene and a sequence for functional mRNA in an expression vector. The expression vector can be transfected into the desired cell type. After transfection of the vector, the effects on a drug on the expression of target gene can be evaluated. The ideal reported gene activity should detect with high sensitivity over any endogenous gene expression. Reporter gene systems permit the use of cancer pathway-specific or developmentally regulated regulatory DNA sequences as markers to analyze gene expression in specific pathways associated with molecular mechanisms of cancer.

β-galactosidase

High-throughput Screening, High Content Screening and Reporter Gene Assays